重症COVID-19与其他重症急性呼吸道感染的神经精神后遗症比较
结果显示两类幸存者后续神经精神诊断和用药风险均高于其余人群,但COVID-19组与SARI组直接比较除抗精神病药处方风险较低外无显著差异。
要点
- COVID-19住院幸存者焦虑HR 2.36、痴呆HR 2.63,均高于其余人群。
- SARI住院幸存者焦虑HR 1.86、痴呆HR 2.55,同样高于其余人群。
- COVID-19组与SARI组直接比较除抗精神病药处方风险较低(HR 0.80)外无显著差异。
核心结论
- 重症COVID-19感染的神经精神后遗症与其他SARI相似,该发现可能为SARI幸存者出院后支持提供参考。
研究设计与样本
- 暴露为COVID-19相关或SARI相关住院(包括重症监护住院),主要结局为出院后12个月随访期间新发神经精神诊断或相关药物首次处方。
主要发现
- 与其余人群相比,SARI和COVID-19住院幸存者后续神经精神诊断风险更高,例如焦虑在SARI幸存者中HR 1.86(95%CI 1.56-2.21),在COVID-19幸存者中HR 2.36(95%CI 2.03-2.74)。
- 痴呆在SARI幸存者中HR 2.55(95%CI 2.17-3.00),在COVID-19幸存者中HR 2.63(95%CI 2.21-3.14)。
- 所有分析药物均观察到类似结果,例如抗抑郁药首次处方在SARI幸存者中HR 2.55(95%CI 2.24-2.90),在COVID-19幸存者中HR 3.24(95%CI 2.91-3.61)。
- COVID-19组与SARI组直接比较除抗精神病药处方风险较低(HR 0.80;95%CI 0.69-0.92)外,无显著差异。
关键数值与推荐
- 随访12个月内新发神经精神诊断包括焦虑、痴呆、精神病、抑郁、双相障碍,相关药物包括抗抑郁药、催眠药/抗焦虑药、抗精神病药。
- 使用灵活参数生存模型估计最大程度调整的风险比(HR)及95%CI。
临床怎么用
- 重症COVID-19幸存者出院后新发神经精神诊断和用药风险较高,与其他SARI幸存者相似。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Individuals surviving severe COVID-19 may be at increased risk of neuropsychiatric sequelae. Robust assessment of these risks may help improve clinical understanding of the post-COVID syndrome, aid clinical care during the ongoing pandemic, and inform postpandemic planning. OBJECTIVE: To quantify the risks of new-onset neuropsychiatric conditions and new neuropsychiatric medication prescriptions after discharge from a COVID-19-related hospitalization, and to compare these with risks after discharge from hospitalization for other severe acute respiratory infections (SARI) during the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, adults (≥18 years of age) were identified from QResearch primary care and linked electronic health record databases, including national SARS-CoV-2 testing, hospital episode statistics, intensive care admissions data, and mortality registers in England, from January 24, 2020, to July 7, 2021. EXPOSURES: COVID-19-related or SARI-related hospital admission (including intensive care admission). MAIN OUTCOMES AND MEASURES: New-onset diagnoses of neuropsychiatric conditions (anxiety, dementia, psychosis, depression, bipolar disorder) or first prescription for relevant medications (antidepressants, hypnotics/anxiolytics, antipsychotics) during 12 months of follow-up from hospital discharge. Maximally adjusted hazard ratios (HR) with 95% CIs were estimated using flexible parametric survival models. RESULTS: In this cohort study of data from 8.38 million adults (4.18 million women, 4.20 million men; mean [SD] age 49.18 [18.45] years); 16 679 (0.02%) survived a hospital admission for SARI, and 32 525 (0.03%) survived a hospital admission for COVID-19. Compared with the remaining population, survivors of SARI and COVID-19 hospitalization had higher risks of subsequent neuropsychiatric diagnoses. For example, the HR for anxiety in survivors of SARI was 1.86 (95% CI, 1.56-2.21) and for survivors of COVID-19 infection was 2.36 (95% CI, 2.03-2.74); the HR for dementia for survivors of SARI was 2.55 (95% CI, 2.17-3.00) and for survivors of COVID-19 infection was 2.63 (95% CI, 2.21-3.14). Similar findings were observed for all medications analyzed; for example, the HR for first prescriptions of antidepressants in survivors of SARI was 2.55 (95% CI, 2.24-2.90) and for survivors of COVID-19 infection was 3.24 (95% CI, 2.91-3.61). There were no significant differences observed when directly comparing the COVID-19 group with the SARI group apart from a lower risk of antipsychotic prescriptions in the former (HR, 0.80; 95% CI, 0.69-0.92). CONCLUSIONS AND RELEVANCE: In this cohort study, the neuropsychiatric sequelae of severe COVID-19 infection were found to be similar to those for other SARI. This finding may inform postdischarge support for people surviving SARI.
引用
- Clift AK, Ranger TA, Patone M, et al. Neuropsychiatric Ramifications of Severe COVID-19 and Other Severe Acute Respiratory Infections. JAMA Psychiatry. 2022. PMID: 35544272. doi:10.1001/jamapsychiatry.2022.1067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。